Facebook Pixel The Future Formula: What's Driving Recruitment Innovation in Pharma | BioSpectrum Asia – business – Lesen Sie diese Geschichte auf Magzter.com

Versuchen GOLD - Frei

The Future Formula: What's Driving Recruitment Innovation in Pharma

BioSpectrum Asia

|

BioSpectrum Asia August 2025

The pharmaceutical recruitment process is becoming more organised, strategic, and data-driven, adapting to changing demands and needs.

- Roop Kaistha

The Future Formula: What's Driving Recruitment Innovation in Pharma

The pharmaceutical and life sciences industry has been undergoing a transformation driven by rapid technological change, demographic shifts, regulatory complexity, and globalisation over the last five years. This shift is especially visible in areas like data science, clinical development, regulatory affairs and digital trials, where the pace of progress demands both depth and flexibility. As organisations respond to faster product cycles and increasingly specialised needs, pharma companies are not behind. Capability-based hiring is becoming central to how they build and manage their teams.

To support this, many companies are deploying focused hiring teams for specific functions such as clinical operations, safety monitoring, and product launch support. These teams, often structured through modular partnerships, allow organisations to access niche talent and expertise at speed without having the need to have a long-term Talent acquisition team. This approach has helped reduce time to hire by 33 per cent and cost to hire by 36 per cent, which is especially valuable when hiring delays risk impacting regulatory timelines or market readiness.

RPOs and Embedded Talent Partners Are Enabling Agility

Recruitment Process Outsourcing (RPO) firms and embedded talent partners are playing a growing role in helping pharma companies stay responsive to shifting demands. By acting as integrated extensions of internal HR teams, these partners are improving hiring speed, ensuring consistency in experience and enabling access to global candidate pools. Their involvement is especially effective in supporting high-growth or expansion markets, where internal teams may not have the capacity or reach.

New Talent Pools Are Emerging in Tier 2 & 3 Cities

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

How FemTech Spurt in APAC is Redefining Healthcare

Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.

time to read

4 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

China's Colossal Ageing Population and Low Birth Rate Challenge

China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.

time to read

2 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"

At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.

time to read

7 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area

Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

NTU and NHG Health partner to advance healthcare education in Singapore

NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"

More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.

time to read

5 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel

Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Royalty Pharma on-boards Kenneth Sun as Senior Vice President and Head of Asia

US-based Royalty Pharma ple has announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Waters launches omniDAWN Multi-Angle Light Scattering (MALS) Photometer

US-based Waters Corporation has announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

South Korea's Cell and Gene Therapy Surge

South Korea's cell and gene therapy (CGT) landscape is highly dynamic, as observed from regulatory approvals, clinical development, and manufacturing activity.

time to read

5 mins

BioSpectrum Asia May 2026

Listen

Translate

Share

-
+

Change font size